Canadian Chronic Disease Surveillance System (CCDSS)

Select item(s) from each list below:

Geography

Condition

Measure

Sex
Both sexes
Males Females
Use the same vertical axis scale across all sex categories

Optional:

Year range

Scale
Use the same vertical axis scale across all geographic areas

Chart type
Line Bar

For more information on the interpretation of the data please see the notes below.

Summary Table: Multiple sclerosis, age-standardized incidence rate, per 100,000, age 20 years and older, Canada
Sex	Fiscal year	Rate (per 100,000)	95% CI	CV (%)	Counts
Both sexes	2003–2004	17	16–17	1.81	3,140
Both sexes	2004–2005	17	16–17	1.79	3,175
Both sexes	2005–2006	16	15–16	1.82	3,075
Both sexes	2006–2007	16	16–17	1.78	3,180
Both sexes	2007–2008	16	15–16	1.82	3,040
Both sexes	2008–2009	16	15–16	1.78	3,165
Both sexes	2009–2010	17	16–17	1.70	3,460
Both sexes	2010–2011	18	17–19	1.63	3,760
Both sexes	2011–2012	14	14–15	1.80	3,085
Both sexes	2012–2013	15	14–15	1.78	3,165
Both sexes	2013–2014	14	14–15	1.80	3,080
Both sexes	2014–2015	15	14–15	1.76	3,235
Both sexes	2015–2016	15	15–16	1.71	3,430
Both sexes	2016–2017	15	14–15	1.73	3,360
Both sexes	2017–2018	15	14–15	1.74	3,350
Both sexes	2018–2019	14	14–15	1.74	3,360
Both sexes	2019–2020	15	14–15	1.71	3,495
Both sexes	2020–2021*	15	15–16	1.68	3,615
Both sexes	2021–2022*	15	14–15	1.70	3,540
Both sexes	2022–2023*	14	13–14	1.75	3,360
Males	2003–2004	10	9–10	3.40	890
Males	2004–2005	10	9–10	3.35	910
Males	2005–2006	10	9–10	3.37	900
Males	2006–2007	9	8–10	3.44	860
Males	2007–2008	10	9–10	3.30	925
Males	2008–2009	9	9–10	3.27	940
Males	2009–2010	12	11–12	2.93	1,170
Males	2010–2011	12	11–13	2.84	1,250
Males	2011–2012	9	9–10	3.23	960
Males	2012–2013	9	8–10	3.23	960
Males	2013–2014	9	8–9	3.29	925
Males	2014–2015	9	8–10	3.17	995
Males	2015–2016	9	9–10	3.12	1,035
Males	2016–2017	9	9–10	3.11	1,045
Males	2017–2018	9	9–10	3.07	1,070
Males	2018–2019	9	8–9	3.12	1,040
Males	2019–2020	10	9–10	2.99	1,140
Males	2020–2021*	10	9–10	2.97	1,155
Males	2021–2022*	9	9–10	3.08	1,075
Males	2022–2023*	9	9–10	3.03	1,115
Females	2003–2004	24	23–25	2.14	2,245
Females	2004–2005	24	23–25	2.12	2,265
Females	2005–2006	22	21–23	2.16	2,175
Females	2006–2007	24	23–25	2.09	2,325
Females	2007–2008	21	20–22	2.18	2,115
Females	2008–2009	22	21–23	2.12	2,225
Females	2009–2010	22	21–23	2.09	2,285
Females	2010–2011	24	23–25	2.00	2,515
Females	2011–2012	20	19–21	2.17	2,125
Females	2012–2013	20	19–21	2.13	2,205
Females	2013–2014	20	19–20	2.16	2,155
Females	2014–2015	20	19–21	2.12	2,235
Females	2015–2016	21	20–22	2.05	2,395
Females	2016–2017	20	19–21	2.09	2,325
Females	2017–2018	20	19–21	2.11	2,285
Females	2018–2019	20	19–21	2.09	2,320
Females	2019–2020	20	19–21	2.08	2,355
Females	2020–2021*	21	20–21	2.04	2,465
Females	2021–2022*	21	20–22	2.04	2,465
Females	2022–2023*	18	18–19	2.14	2,240

Download Detailed Table:
Multiple sclerosis, age-standardized incidence rate

Download Summary Table

Notes:

*Many CCDSS measures, such as chronic disease incidence, were influenced by the COVID-19 pandemic. Changes in such measures may be driven by multiple factors, including (but not limited to) differences in healthcare seeking behaviour, the availability and use of healthcare services, as well as true changes in health status. As such, CCDSS measures should be used cautiously when making inferences about population health during the COVID-19 pandemic. Guidance for data users on examining the impacts of the COVID-19 pandemic on CCDSS measures can be accessed below.
Data suppression: Estimates are not reported when the counts are less than 10 or the coefficient of variation is greater than 33.3%.
Due to periodic updates of the historical surveillance data, estimates for a particular disease and year may change over time, and may not be comparable to previous editions.
Estimates are age-standardized to the 2011 Canadian population using unrounded counts and five-year age groups. Age-standardized estimates are useful for comparing data across years or between different geographical areas, but they do not reflect the actual impact of the disease.
Nunavut data are excluded before 2005–2006.
Newfoundland and Labrador data are excluded before 2008–2009.
The introduction of the Northwest Territories Electronic Medical Record (EMR) in 2016 resulted in more complete and consistent data. Data for 2016–2017 may be slightly underestimated compared to previous years due to the system transition.
New Brunswick data were not available for 2021–2022 and 2022–2023.
Quebec data were not available.
Yukon data are excluded.
Northwest Territories data were not available for 2022–2023.
Northwest Territories physician claim data were incomplete for 2021–2022 and should therefore be interpreted with caution, as a slight underestimation is suspected.

Source: Canadian Chronic Disease Surveillance System 2024
Methods: CCDSS Summary of Methods
Case definitions: CCDSS Case Definitions
COVID-19 Documentation: CCDSS COVID-19 guidance for data users

Acknowledgements

These data were made possible through collaboration between PHAC and the respective provincial and territorial governments of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and Labrador, Northwest Territories, Yukon, and Nunavut. No endorsement by the provinces and territories is intended or should be inferred. Provincial and territorial data were contributed to the CCDSS as of July 2024.

Language selection

Search

Canadian Chronic Disease Surveillance System (CCDSS)

Select item(s) from each list below:

Optional:

Acknowledgements

Did you find what you were looking for?